Australië - Engels - Department of Health (Therapeutic Goods Administration)

md solutions australasia pty ltd -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - analgesia (adults and children over 12 years of age) ? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain (excluding intermittent top up injections) ? field block (minor nerve block and infiltration) ? continuous peripheral nerve block infusion or intermittent injections for post ? operative pain management ? continuous wound infusion for postoperative pain management (adults only) analgesia (children aged 0 - 12 years) ? continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years,for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine-aft for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - analgesia (adults and children over 12 years of age) ? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain (excluding intermittent top up injections) ? field block (minor nerve block and infiltration) ? continuous peripheral nerve block infusion or intermittent injections for post ? operative pain management ? continuous wound infusion for postoperative pain management (adults only) analgesia (children aged 0 - 12 years) ? continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years,for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine-aft for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

cigweld pty ltd -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medical equipment & gases australia - 16953 - analgesia unit, inhalation - delivery of a variable analgesic gas mixture of nitrous oxide and oxygen for the demand inhalation of patients, to relieve pain in situations such as obstetrics, minor surgery, burn dressing, and transport of accident victims.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

swirl technologies pty ltd t/a parker healthcare -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

gascon systems ltd -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

md solutions australasia pty ltd -

Singapore - Engels - HSA (Health Sciences Authority)

medtronic international, ltd. - cardiovascular - medtronic sensia implantable pulse generators(ipgs) are indicated for use to improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. these devices are indicated for use in patients who are experiencing exercise intolerance or exercise restrictions related to an arrhythmia. using rate response modes may restore heart rate variability and improve cardiac output. sensia d/dr series implantable pulse generators are indicated for single use only.

Singapore - Engels - HSA (Health Sciences Authority)

medtronic international, ltd. - cardiovascular - medtronic sensia implantable pulse generators (ipgs) are indicated for use to improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. these devices are indicated for use in patients who are experiencing exercise intolerance or exercise restrictions related to an arrhythmia. using rate response modes may restore heart rate variablility and improve cardiac output. sensia dr series implantable pulse generators are indicated for single use only.